
Avenge Bio’s AVB-001 Granted FDA Orphan Drug Designation for Mesothelioma Treatment
Avenge Bio, Inc., a leading biotech firm specializing in oncology, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AVB-001. This designation recognizes AVB-00 ...